[1]赵春红,李 楠.特利加压素结合人血白蛋白治疗肝硬化顽固性腹水的效果[J].医学信息,2020,33(06):150-151.[doi:10.3969/j.issn.1006-1959.2020.06.049]
　ZHAO Chun-hong,LI Nan.Effect of Terlipressin Combined with Human Albumin on Refractory Ascites Due to Cirrhosis[J].Medical Information,2020,33(06):150-151.[doi:10.3969/j.issn.1006-1959.2020.06.049]
点击复制

特利加压素结合人血白蛋白治疗肝硬化顽固性腹水的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年06期
页码:
150-151
栏目:
药物与临床
出版日期:
2020-03-15

文章信息/Info

Title:
Effect of Terlipressin Combined with Human Albumin on Refractory Ascites Due to Cirrhosis
文章编号:
1006-1959（2020）06-0150-02
作者:
赵春红; 李 楠
（佳木斯市中心医院感染科，黑龙江 佳木斯 154002）
Author(s):
ZHAO Chun-hong; LI Nan
(Department of Infectious Diseases,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
人血白蛋白; 肝硬化; 顽固性腹水; 血清生化指标
Keywords:
Human albumin; Cirrhosis; Refractory ascites; Serum biochemical indicators
分类号:
R575.2
DOI:
10.3969/j.issn.1006-1959.2020.06.049
文献标志码:
A
摘要:
目的 分析特利加压素结合人血白蛋白治疗肝硬化顽固性腹水的临床效果及对血清生化指标的影响。方法 选择2018年6月~2019年6月在我院诊治的肝硬化顽固性腹水患者76例，采用随机数字表法分为对照组和观察组，各38例。对照组采用人血白蛋白治疗，观察组在对照组基础上采用特利加压素治疗，比较两组临床治疗总有效率、血清白蛋白（ALB）、血肌酐（Scr）、24 h尿钠排量。结果 观察组治疗总有效率为92.10%，高于对照组为78.94%，差异有统计学意义（P＜0.05）；治疗后两组ALB、24 h尿钠排量大于治疗前，Scr水平低于治疗前，且观察组ALB、24 h尿钠排量大于对照组，Scr水平低于对照组，差异均有统计学意义（P＜0.05）。结论 特利加压素结合人血白蛋白治疗肝硬化顽固性腹水的效果理想，有助于改善临床患者症状和血清生化指标，值得临床应用。
Abstract:
Objective To analyze the clinical effect of terlipressin combined with human serum albumin in the treatment of refractory ascites due to cirrhosis and the effect on serum biochemical parameters.Methods A total of 76 patients with refractory ascites of liver cirrhosis diagnosed and treated in our hospital from June 2018 to June 2019 were selected and divided into control group and observation group by random number table method, with 38 cases in each group. The control group was treated with human serum albumin, and the observation group was treated with terlipressin on the basis of the control group. The total effective rate of clinical treatment, serum albumin (ALB), serum creatinine (Scr), and 24 h urine sodium were compared between the two groups.Results The total effective rate of treatment in the observation group was 92.10%, which was higher than the control group by 78.94%,the difference was statistically significant (P<0.05). After treatment, the ALB and 24 h urine sodium output of the two groups were greater than before treatment, and the Scr level was lower than before treatment. The observation group had greater ALB and 24 h urine sodium excretion than the control group, and the Scr level was lower than the control group,the differences were statistically significant (P <0.05).Conclusion Terlipressin combined with human albumin is effective in the treatment of refractory ascites due to cirrhosis, and it is helpful to improve the clinical symptoms and serum biochemical parameters of clinical patients.

参考文献/References:

[1]肖丹,程波.米多君与特利加压素对肝硬化腹水患者血流动力学影响效果比较的临床观察[J].临床内科杂志,2016,33(7):467-468.[2]张会涛,李秋雅,吕文浩,等.特利加压素联合人血白蛋白治疗肝硬化顽固性腹水的临床疗效观察[J].实用医院临床杂志,2018,15(6):115-117.[3]李绥邦,马婷婷.特利加压素辅助治疗中重度肝硬化腹水的临床效果极其对肝肾功能、门脉系统内径的影响[J].山东医药,2016,56(40):78-80.[4]黄瑞华.保肝利水汤联合西药治疗乙肝肝硬化顽固性腹水临床观察[J].陕西中医,2016,37(11):1443-1444.[5]杨军.注射用特利加压素治疗肝硬化顽固性腹水临床观察[J].药物流行病学杂志,2015,24(2):75-77.

相似文献/References:

[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
　CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Medical Information,2018,31(06):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]张铁彪,刘建华,马长顺.肺癌肿瘤标记物结合胸部CT检查肺结节的定性分析[J].医学信息,2022,35(10):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
　ZHANG Tie-biao,LIU Jian-hua,MA Chang-shun.Qualitative Analysis of Lung Cancer Tumor Markers Combined with Chest CT Examination of Pulmonary Nodules[J].Medical Information,2022,35(06):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
[4]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
　ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Medical Information,2019,32(06):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
[5]郑 瑜.人血白蛋白联合中药治疗卵巢过度刺激综合征患者的疗效观察[J].医学信息,2019,32(04):151.[doi:10.3969/j.issn.1006-1959.2019.04.049]
　ZHENG Yu.Therapeutic Effect of Human Serum Albumin Combined with Traditional Chinese Medicine on Patients with Ovarian Hyperstimulation Syndrome[J].Medical Information,2019,32(06):151.[doi:10.3969/j.issn.1006-1959.2019.04.049]
[6]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Medical Information,2018,31(06):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[7]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Medical Information,2018,31(06):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[8]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
　ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(06):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[9]姜海燕.双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J].医学信息,2022,35(12):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
　JIANG Hai-yan.Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis[J].Medical Information,2022,35(06):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
[10]张许林,余泽波.肝硬化上消化道出血的输血治疗进展[J].医学信息,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
　ZHANG Xu-lin,YU Ze-bo.Progress in Transfusion Therapy for Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(06):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]

更新日期/Last Update: 2020-03-15